M ultiple brain metastases are found in up to 61% of patients at diagnosis. 1 The goal of treatment of patient with brain metastases, single or multiple, is that of palliating and/or preventing neurological symptoms, while also maintaining a good quality of life.
ABBREVIATIONS: CNS, central nervous system; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy
In this context, surgery and radiation (focal or otherwise) have represented the mainstay of treatment. Lately, targeted therapies for some cancers have shown central nervous system (CNS) activity, to a degree, making them a useful adjunct in the treatment of brain metastases.
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METHODS
The PubMed, Embase, and Cochrane CENTRAL online databases were searched for the period of MULTIPLE BRAIN METASTASES THERAPY January 1, 2000 through December 31, 2015. Citations and references then screened using the predetermined inclusion and exclusion criteria. The reference lists of the most relevant and most recent articles were also reviewed, and additional articles were selected for initial review. Those meeting criteria were then retrieved for full-text review and assessment of bias. Those that were informative were chosen for evidence table creation, classified, and used for creation of recommendations as per the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) methods (https://www.cns.org/guidelines/guideline-procedures-policies/guideline -development-methodology).
RESULTS
Upon evaluating the qualifying data on when whole brain radiation is recommended in patients with multiple brain metastases, information must be extracted from studies where it is combined with other therapies. There is one class I prospective randomized study analyzing patients with 1 to 3 brain metastases allocated to whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) or SRS alone, designed to evaluate neurocognition (a primary endpoint). 4 In this study, withholding WBRT in favor of radiosurgery alone was associated with improved neurocognition and increased survival, but decreased local and distant control. Another prospective randomized study analyzed patients with 1 to 4 brain metastases treated with WBRT + SRS vs SRS alone. 5 Local and distant failures as well as salvage treatment were significantly less in WBRT + SRS than SRS alone. However, no difference in the cause of death between the 2 groups was detected. Another class II study looked at patients with 1 to 3 brain metastases treated with surgery or SRS + WBRT vs surgery or SRS alone. 6 There was no difference in functional independence (primary endpoint), and data on the WBRT effect could not be fully differentiated. Multiple class III studies describe the value of radiosurgery and of WBRT in the management of multiple brain metastases. [7] [8] [9] [10] Taken together, these studies do not lead the clinician to a specific decision. Thus, class II data suggest that WBRT can be added in cases of multiple metastases to improve local and distant CNS control but the managing physician must recognize that this may have an adverse effect on neurocognitive function and that it is unlikely to improve overall survival.
Again, when looking at the value of SRS in the management of multiple metastases information must be extracted from studies where it is combined with other therapies. There is one class I study showing that in patients with 1 to 3 brain metastases not amenable to surgery, the addition of SRS to WBRT does not improve survival compared to WBRT alone, both in the whole group and in the group with 2 to 3 brain metastases. 11 There is one prospective randomized study showing that SRS + WBRT is superior to WBRT alone in patients with 2 to 4 brain metastases in terms of local control (primary endpoint). 12 However, this study is underpowered, and its findings relating to local control have never been replicated. 12 The results of a multiinstitutional prospective observational noninferiority study show that in patients with 2 to 4 vs 5 to 10 metastases treated with SRS, overall survival (OS) is the same (primary endpoint). 13 Thus, it can be stated that it is safe and effective to use focal radiation therapy to improve local control, but not extend overall survival, in the treatment of patients with multiple brain metastases.
Upon evaluating the value of surgery in the management of multiple metastases, class III evidence was available. Its evaluation was often in conjunction with other modalities. Bindal et al reported on a case series of 56 patients with multiple brain metastases treated with surgery and WBRT. 14 The authors concluded that "…surgical removal of all lesions in selected patients with multiple brain metastases results in significantly increased survival time and gives a prognosis similar to that of patients undergoing surgery for a single metastasis." 14 Iwadate et al 15 investigated the role of surgery and WBRT in the treatment of 138 patients with single and multiple brain metastases. Median survival times were 8.7 mo for patients with single metastases and 9.2 mo for patients with multiple metastases, showing no significant difference. 15 Pollock et al 16 reported on a retrospective case series of 52 patients with multiple brain metastases treated with a combination of WBRT, surgery, and SRS. The authors concluded that "wellselected patients with multiple brain metastases appear to benefit from surgery and SRS compared to historical controls of patients treated with WBRT alone." In summary, the use of surgery in treating multiple brain metastases may be beneficial in patients with accessible symptomatic lesions, and controlled or treatable primary disease.
DISCUSSION
Surgery may be of benefit in those patients with multiple brain metastases under selected circumstances as noted above. Otherwise, WBRT or SRS should both be considered as valid primary therapies. They are also useful therapeutic modalities after surgical resection. Targeted systemic therapies are another variable to be considered when individualizing therapy in patients with multiple brain metastases. 17, 18 There is a need for robust class I studies addressing the necessity of WBRT, focal therapy (SRS and/or surgery), and targeted systemic therapies in patients with multiple brain metastases.
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